NSE: LALPATHLAB | BSE: 539524

Mid-range Performer

Download real time

2960.10 85.40 (2.97%)

29.06% Gain from 52W Low

210.3K NSE+BSE Volume

NSE 10 Jun, 2025 3:31 PM (IST)

24,798.4

Market Cap

Market Runner Up

0.4

Beta 1Year

Very Low volatility

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd.

06 Aug 2020

2960.10

2.97%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

The company's growth in COVID business, strong brand recall, gradual unlock of cities should support growth in upcoming quarters. Given the limited upside potential we downgrade our rating to HOLD with a revised target price of Rs. 1,995 based on 53x FY22E EPS. COVID-19 tests contribute to the top line DLPL's Q1FY21 top line went down 20.6% YoY to Rs. 266cr severely impacted by COVID-19 and subsequent lock down impacting the revenue in April (-61% YoY) and May (-12% YoY), however some respite was seen in June (+14% YoY) when cities were...

Dr. Lal Pathlabs Ltd.'s price crossed above 200Day SMA today

Dr. Lal Pathlabs Ltd.

03 Aug 2020

2960.10

2.97%

Q1FY21 Result Update - COVID test paper covers the cracks of slowdown - SELL

Sell: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

We remain negative on the entire diagnostic chain with a belief of 1) premium players losing their market share to unorganized players, 2) B2B (40% of revenue) partners negotiating to partially offset their loss of profit, 3) Inability to hike prices causing lower realization level (Revenue/Patient) and 4) higher fixed costs (60-65% of operating cost for DLPL), new compliance expense and home collection of samples will lead to lower EBITDA margin. However even after increased estimate, we maintain SELL' recommendation but revised TP to Rs1,006 (from Rs895) on PE 40x of FY22E due to challenging...

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

19 May 2020

2960.10

2.97%

Q4FY20 Result Update - Core biz recovery unlikely in near term; Downgrade to Sell

Sell: Dr. Lal Pathlabs Ltd.

Recommendation Target

Prabhudas Lilladhar

28-30% of revenue compared to last year in Q1FY21E and gradual recovery from Q2FY21E. As per the management, 60-65% of DLPL's total operating cost is fixed in nature and the new additional expense (cost of safety for...

Dr. Lal Pathlabs Ltd.'s price crossed above 200Day SMA today

Dr. Lal Pathlabs Ltd.

20 Apr 2020

2960.10

2.97%

DR. LAL PATHLABS LIMITED

Buy: Dr. Lal Pathlabs Ltd.

Geojit BNP Paribas

DLPL's strong business model led to a revenue growth of 16.2% CAGR over FY15-19, supported by rise in sample collection (~18.6% CAGR; backed by large network of PSCs 1,600 and PUPs) along with growing number of patient served (+15.5% CAGR). Company's 1,200 Hub and Spoke model (centralized diagnostic testing) offers economies of scale and 800...

Dr. Lal Pathlabs Ltd.'s price crossed above 200Day SMA today

Dr. Lal Pathlabs Ltd.

22 Aug 2019

2960.10

2.97%

Dr. Lal PathLabs Ltd: Planned Expansions Boost Revenues

Hold: Dr. Lal Pathlabs Ltd.

Karvy

Dr Lal PathLabs (DLPL) Q1FY20 earnings came marginally higher than our estimates on account of improved revenue contribution from regions constituting

Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.

Dr. Lal Pathlabs Ltd.

14 Aug 2019

2960.10

2.97%

Q1FY20 Result Update

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

DLPL's revenue, adj. EBITDA and PAT grew 15%, 21% and 19% YoY Change in Estimates | Target | Reco With strong cash flow and growth in new customers and packaged offer, the...

Dr. Lal Pathlabs Ltd.'s price crossed above 200Day SMA today

Dr. Lal Pathlabs Ltd.

11 Feb 2019, 12:00AM

2960.10

2.97%

Q3FY19 Result Update - Q3 in line; Muted Dengue season leads tepid Q3

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

DLPL's revenue, adj. EBITDA and PAT grew 11%, 16% and 27% YoY Change in Estimates | Target | Reco respectively in Q3FY19 and in line with our estimates in margin and earnings. With strong cash flow and growth in new customers and packaged offer, the...